…
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Income before tax | 257.50M | 284.19M | 276.02M | -93.92M | 262.46M |
| Net income | 190.30M | 214.60M | 209.34M | -82.31M | 205.38M |
| Selling general administrative | 116.45M | 108.21M | 106.15M | 107.35M | 108.52M |
| Selling and marketing expenses | 148.78M | 155.72M | 153.31M | 145.06M | 157.34M |
| Gross profit | 574.64M | 634.46M | 624.45M | 625.29M | 620.65M |
| Reconciled depreciation | 31.27M | 30.17M | 30.68M | 32.62M | 32.09M |
| Ebit | 299.83M | 331.82M | 343.19M | 345.47M | 329.92M |
| Ebitda | 331.11M | 361.99M | 373.86M | 378.09M | 360.96M |
| Depreciation and amortization | 31.27M | 30.17M | 30.68M | 32.62M | 31.04M |
| Non operating income net other | - | - | - | -2.34M | -3.17M |
| Operating income | 309.41M | 336.77M | 342.43M | 345.47M | 329.92M |
| Other operating expenses | 779.30M | 800.99M | 782.93M | 779.92M | 756.89M |
| Interest expense | 42.34M | 47.63M | 67.16M | 69.16M | 64.29M |
| Tax provision | 67.19M | 69.58M | 66.69M | -11.61M | 57.08M |
| Interest income | - | 47.63M | 67.16M | 69.16M | 64.29M |
| Net interest income | -42.34M | -47.63M | -67.16M | -69.16M | -64.29M |
| Non recurring | - | - | - | 370.22M | - |
| Income tax expense | 67.19M | 69.58M | 66.69M | -11.61M | 57.08M |
| Total revenue | 1088.70M | 1137.76M | 1125.36M | 1127.72M | 1086.81M |
| Total operating expenses | 265.23M | 297.69M | 282.02M | 277.49M | 290.73M |
| Cost of revenue | 514.07M | 503.30M | 500.91M | 502.43M | 466.17M |
| Total other income expense net | -51.91M | -52.59M | -66.40M | -439.38M | -67.46M |
| Net income from continuing ops | 190.30M | 214.60M | 209.34M | -82.31M | 205.38M |
| Net income applicable to common shares | - | 214.60M | 209.34M | -82.31M | 205.38M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Total assets | 3547.57M | 3402.22M | 3318.42M | 3353.73M | 3670.68M |
| Intangible assets | 2299.61M | 2295.35M | 2320.58M | 2341.89M | 2696.64M |
| Other current assets | 16.56M | 8.44M | 13.08M | 4.12M | 6.41M |
| Total liab | 1660.05M | 1567.32M | 1663.33M | 1906.64M | 2093.07M |
| Total stockholder equity | 1887.52M | 1834.90M | 1655.08M | 1447.08M | 1577.61M |
| Other current liab | 85.58M | 78.33M | 69.35M | 88.21M | 78.55M |
| Common stock | 0.56M | 0.56M | 0.56M | 0.55M | 0.54M |
| Capital stock | 0.56M | 0.56M | 0.56M | 0.55M | 0.54M |
| Retained earnings | 1746.10M | 1555.80M | 1341.20M | 1131.86M | 1214.16M |
| Other liab | - | - | - | - | 452.40M |
| Good will | 581.11M | 527.42M | 527.73M | 527.55M | 578.98M |
| Other assets | - | 3.27M | 0.00M | 3.00M | 3.27M |
| Cash | 63.87M | 97.88M | 46.47M | 58.49M | 27.18M |
| Cash and equivalents | - | 97.88M | 46.47M | 58.49M | 27.18M |
| Total current liabilities | 120.92M | 106.62M | 117.05M | 160.72M | 143.42M |
| Current deferred revenue | - | - | 2.57M | - | - |
| Net debt | 981.56M | 946.37M | 1093.19M | 1308.60M | 1479.17M |
| Short term debt | 12.55M | 8.54M | 6.15M | 9.76M | 9.11M |
| Short long term debt | 2.99M | - | - | - | - |
| Short long term debt total | 1045.43M | 1044.25M | 1139.66M | 1367.09M | 1506.36M |
| Other stockholder equity | 169.22M | 316.19M | 347.83M | 346.24M | 381.94M |
| Property plant equipment | - | 127.84M | 89.33M | 70.41M | 71.30M |
| Total current assets | 431.48M | 448.33M | 375.04M | 391.74M | 293.27M |
| Net tangible assets | - | - | - | 1447.08M | 1577.61M |
| Net receivables | 191.92M | 194.29M | 176.78M | 167.02M | 139.33M |
| Long term debt | 993.95M | 992.36M | 1125.80M | 1345.79M | 1476.66M |
| Inventory | 159.13M | 147.71M | 138.72M | 162.12M | 120.34M |
| Accounts payable | 22.79M | 18.93M | 38.98M | 62.74M | 55.76M |
| Accumulated other comprehensive income | -28.37M | -37.66M | -34.49M | -31.56M | -19.03M |
| Common stock total equity | - | - | - | 0.55M | 0.54M |
| Retained earnings total equity | - | - | - | 1131.86M | 1214.16M |
| Treasury stock | - | - | - | - | -133.65M |
| Non currrent assets other | 2.17M | 3.27M | 5.72M | -377.43M | 3.27M |
| Non current assets total | 3116.09M | 2953.89M | 2943.37M | 2961.99M | 3377.41M |
| Capital lease obligations | 48.49M | 51.89M | 13.85M | 21.30M | 29.70M |
| Long term debt total | - | 1012.98M | 1125.98M | 1347.45M | 1481.16M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Investments | - | -17.45M | -20.11M | -11.58M | -256.51M |
| Change to liabilities | - | - | - | 18.00M | 18.77M |
| Total cashflows from investing activities | -136.84M | -17.45M | -20.11M | -11.58M | -256.51M |
| Net borrowings | 0.50M | -139.54M | -227.83M | -135.00M | -9.11M |
| Total cash from financing activities | -156.06M | -182.07M | -241.01M | -185.85M | -7.57M |
| Change to operating activities | - | - | - | - | 3.89M |
| Net income | 190.30M | 214.60M | 209.34M | -82.31M | 205.38M |
| Change in cash | -34.02M | 51.41M | -12.02M | 31.30M | -5.12M |
| Begin period cash flow | 97.88M | 46.47M | 58.49M | 27.18M | 32.30M |
| End period cash flow | 63.87M | 97.88M | 46.47M | 58.49M | 27.18M |
| Total cash from operating activities | 257.63M | 251.51M | 248.93M | 229.72M | 259.92M |
| Depreciation | 31.27M | 30.17M | 30.68M | 32.62M | 32.09M |
| Other cashflows from investing activities | -1.93M | -9.23M | -10.56M | -3.80M | -246.87M |
| Change to inventory | -1.60M | -9.31M | 24.44M | -42.23M | 0.66M |
| Change to account receivables | -3.69M | -16.33M | -6.32M | -24.93M | -24.65M |
| Sale purchase of stock | -156.28M | -51.51M | -25.00M | -50.00M | 7.04M |
| Other cashflows from financing activities | -4.57M | -5.83M | 11.81M | 14.53M | 680.01M |
| Change to netincome | - | - | - | 322.58M | 22.46M |
| Capital expenditures | 11.18M | 8.22M | 9.55M | 7.78M | 9.64M |
| Change receivables | - | - | - | -24.93M | -24.65M |
| Cash flows other operating | - | - | - | 1.61M | 0.98M |
| Cash and cash equivalents changes | - | - | - | 32.29M | -4.16M |
| Change in working capital | -17.62M | -41.94M | -39.83M | -53.85M | -10.95M |
| Stock based compensation | 10.84M | 11.16M | 14.01M | 12.40M | 9.04M |
| Other non cash items | 20.14M | 23.11M | 11.66M | 381.61M | 14.38M |
| Free cash flow | 246.45M | 243.29M | 239.38M | 221.93M | 250.28M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PBH Prestige Brand Holdings Inc |
-0.80 1.78% |
44.17 | 13.08 | 10.71 | 2.00 | 1.18 | 3.83 | 13.54 |
| MKKGY Merck KGaA ADR |
0.13 0.39% |
33.80 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
169.12 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
- -% |
20.84 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.72 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
660 White Plains Road, Tarrytown, NY, United States, 10591
914 524 6800
890
| Name | Title | Year Born |
|---|---|---|
| Mr. Ronald M. Lombardi | Chairman, Pres & CEO | 1964 |
| Ms. Christine Sacco | Chief Financial Officer | 1976 |
| Mr. Jeffrey Zerillo | Sr. VP of Operations | 1961 |
| Mr. William C. P'Pool | Sr. VP, Gen. Counsel & Corp. Sec. | 1965 |
| Mr. Adel Mekhail | Exec. VP of Marketing & Sales | 1961 |
| Mr. Philip David Terpolilli | Director of Investor Relations | NA |
| Dean Siegal | Director of Communications | NA |
| Ms. Mary Beth Fritz | Sr. VP of Quality & Regulatory Affairs | NA |
| Mr. Ronald M. Lombardi CPA | Chairman, President & CEO | 1964 |
| Ms. Christine Sacco CPA | CFO & COO | 1976 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.